Neurotrophic factor production accelerator

Abstract

The present invention relates to an a neurotrophic factor production accelerator comprising, as an active ingredient, a compound represented by the formula (I) below: wherein R<1> is lower alkyl, aryl, ar(lower)alkoxy, or a heterocyclic group, and the above groups may be substituted with halogen, R<2> is a hydrogen atom or lower alkyl, R<3> is cyclo(lower)alkyl, aryl or ar(lower)alkyl, and the above groups may be substituted with halogen, A is -CO-, -SO2- or lower alkylene, X is N or CH, Y is -CO-, -SO2- or -CONH-, a salt, a prodrug or a solvate thereof. According to the present invention, a neurotrophic factor production accelerator, which is useful for the prophylaxis or treatment of a motor nervous system or peripheral nervous system disease, can be provided.

Description

technical field [0001] The present invention relates to an agent for promoting the production of neurotrophic factors. The present invention also relates to a drug for preventing and treating diseases of the motor nervous system and peripheral nervous system, which contains a compound with the effect of promoting the production of neurotrophic factors as an active ingredient. Background technique [0002] Neurotrophic factors are endogenous factors involved in the differentiation, survival, function maintenance of nerve cells, elongation of neurites depending on the concentration gradient, etc., known as glial cell-derived neurotrophic factor (hereinafter also referred to as GDNF), Nerve growth factor (hereinafter also referred to as NGF), brain-derived neurotrophic factor (hereinafter also referred to as BDNF), ciliary neurotrophic factor (hereinafter also referred to as CNTF), neurotrophin 3 (hereinafter also referred to as NT-3) , insulin-like growth factor (hereinafter ...

AI Technical Summary

Problems solved by technology

[0003] However, neurotrophic factors are high-molecular-weight proteins with poor intestinal absorption, and satisfactory effects cannot be obtained by oral administration.

Therefore, it is necessary to administer drugs through intravenous injection, etc., which increases the economic burden on patients.

In addition, the metabolic stability in the body is also poor, and good effects cannot be expected in many cases.

Moreover, it is also difficult to prepare large quantities of neurotrophic factors

Therapeutic use of neurotrophic factors per se is problematic and often difficult

Images